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Objectives: We aimed to examine the effects and safety of accelerated intermittent
Theta Burst Stimulation (iTBS) on suicide risk in a group of treatment-resistant unipolar
depressed patients, using an extensive suicide assessment scale.
Methods: In 50 therapy-resistant, antidepressant-free depressed patients, an intensive
protocol of accelerated iTBS was applied over the left dorsolateral prefrontal cortex
(DLPFC) in a randomized, sham-controlled crossover design. Patients received 20 iTBS
sessions over 4 days. Suicide risk was assessed using the Beck Scale of Suicide
ideation (BSI).
Results: The iTBS protocol was safe and well tolerated. We observed a significant
decrease of the BSI score over time, unrelated to active or sham stimulation and
unrelated to depression-response. No worsening of suicidal ideation was observed.
The effects of accelerated iTBS on mood and depression severity are reported in Duprat
et al. (2016). The decrease in suicide risk lasted up to 1 month after baseline, even in
depression non-responders.
Conclusions: This accelerated iTBS protocol was safe. The observed significant
decrease in suicide risk was unrelated to active or sham stimulation and unrelated to
depression response. Further sham-controlled research in suicidal depressed patients
is necessary. (Clinicaltrials.gov identifier: NCT01832805).
Keywords: repetitive transcranial magnetic stimulation, suicide, suicidal ideation, depression, therapy-resistant
depression, theta burst stimulation
INTRODUCTION
Worldwide, over 800,000 people die of suicide every year and the number of non-fatal suicide
attempts is estimated to be more than twenty times higher (WHO, 2014 report). Except
for electroconvulsive therapy (ECT), few treatments for suicidal ideation and behavior (e.g.,
lithium, ketamine and clozapine) are available and these are only partially effective (Sher
et al., 2010). Furthermore, the utility of ECT is limited due to safety concerns and adverse events.
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There thus is a great need for more convenient interventions with
a rapid effect on suicide risk in order to prevent suicide.
Repetitive Transcranial Magnetic Stimulation (rTMS) has
well-documented positive effects on depression without major
side effects (Schutter, 2009). A review of the literature indicates
that rTMS improves several preconditions for suicide, including
mood, memory, attention, executive functioning and other
neuropsychological dysfunctions, such as choosing immediate
reward over larger, delayed rewards (Figner et al., 2010; Sher
et al., 2010). Moreover, rTMS is thought to have molecular
effects similar to those seen with ECT, which is also applied in
suicidal patients, such as increased BDNF, increased monoamine
turnover and normalization of the hypothalamic-pituitary-
adrenal axis (George, 2010). Several researchers have reported
an acute decrease of suicidal ideations following treatment with
rTMS (O’Reardon et al., 2007; Holtzheimer et al., 2010; Hadley
et al., 2011; Keshtkar et al., 2011; Wall et al., 2011; Desmyter
et al., 2014; George et al., 2014). These results however were
considered as preliminary because all but one were not sham-
controlled while mostly very limited suicide assessmentmeasures
were used and sample sizes were relatively small. Thus, these
preliminary results need to be substantiated by sham-controlled
studies in larger groups of patients with more elaborate suicide
assessment and longer follow-up. A systematic review and meta-
analysis by Brunoni et al. (2009) indeed reported that placebo-
response in depression is large in rTMS and antidepressant
trials. In the only rTMS study that has used a sham-control,
a significant decrease in suicide risk was observed but no
significant difference between the TMS and the sham group
(George et al., 2014).
Furthermore, previous rTMS research in depression has
shown a dose-response relationship and more recently, studies
have shown a trend towards administering more stimuli over
a shorter period of time and at higher frequencies leading
to accelerated protocols (Holtzheimer et al., 2010; Baeken
et al., 2013; George et al., 2014). In addition, Theta Burst
Stimulation (TBS) uses bursts of high frequency stimulation
at repeated intervals and is thought to affect brain function
more thoroughly when compared to ‘‘classic’’ rTMS (Huang
et al., 2005; Di Lazzaro et al., 2008). Intermittent Theta
Burst Stimulation (iTBS) induces a long-term potentiation
(LTP)-like effect by increasing the postsynaptic concentration
of calcium ions (Huang et al., 2009, 2011; Oberman et al.,
2011). TBS has been applied to depression in several
studies (Chistyakov et al., 2010; Li et al., 2014): it appeared
to be safe and well tolerated and to have antidepressant
properties.
For the current randomized, sham-controlled cross-over
study, we aimed to examine the effect of accelerated iTBS
on suicide risk in a group of treatment-resistant unipolar
depressed patients, using an extensive suicide assessment scale.
We hypothesized that this intensified treatment protocol would
be safe in depressed patients with suicide ideation and would
result in significant decreases in suicide risk in the active and
not in the sham condition. To our knowledge this is the first
study investigating accelerated iTBS as an intervention to reduce
suicide risk.
Subjects and Methods
This registered study was approved by the ethical committee
of the Ghent University Hospital and all subjects gave written
informed consent. It was part of a larger project investigating
the effects of accelerated iTBS on depressive symptoms and
suicide risk (clinicaltrials.gov identifier: NCT01832805). Part
of this data set, including 12 patients, was also used in a
conference article reporting preliminary results on the effects
of accelerated iTBS on the SSI (Beck scale for suicidal ideation;
Desmyter et al., 2014). The effects of accelerated iTBS on
mood and depression severity are reported in Duprat et al.
(2016).
Patients were screened using the structured Mini
International Neuropsychiatric Interview (MINI; Sheehan
et al., 1998). The 17-items Hamilton Depression Rating Scale
(HDRS) was administered by an independent rater, and
patients were required to have a minimum score of 14, which
is defined as at least moderate depression (Hamilton, 1967).
Patients were at least stage I therapy-resistant depressed,
according to the Thase and Rush staging model, indicating
the failure of at least one adequate trial of one major class of
antidepressants (Thase and Rush, 1997). Depressed patients were
diagnosed, screened and included several weeks before baseline
because, when approved, antidepressant and antipsychotic
medication and mood stabilizers were tapered off and stopped
2 weeks before the start and during the whole period of
the iTBS treatment in order to evaluate the treatment in
monotherapy.
Fifty therapy-resistant antidepressant-free patients were
included (35 females), with a mean age of 41.90 years
(SD = 11.77). Patients with the following conditions were
excluded: psychotic symptoms, history of epileptic insult,
cerebral surgery, having a pacemaker, having had ECT, alcohol
dependence and patients who committed a suicide attempt
within 6 months before the start of the study. Bipolar and
psychotic depressed patients were not included. The 21-items
Beck Scale for Suicide Ideation (BSI) was used to assess the
intensity of the patients’ suicide risk. The BSI is a self-rating
scale that measures the current intensity of the patients’ suicidal
ideations, intentions and plans to commit suicide. Each item
consists of three options graded according to suicidal intensity
ranging from 0 to 2. The total score is yielded by the sum of
the ratings for the first 19 items, ranging from 0 to 38. The
BSI consists of five screening items. Three items assess the
wish to live or the wish to die and two assess the desire to
attempt suicide. If the subject reports any active or passive desire
to commit suicide, then 14 additional items are administered.
These consist of suicidal risk factors such as the duration and
frequency of ideation, sense of control over making an attempt,
number of deterrents, and amount of actual preparation for a
contemplated attempt. Two additional items record incidence
and frequency of previous suicide attempts (Beck et al., 1988;
Beck and Steer, 1991). There were four time-points for evaluation
at which depression severity was evaluated using the HDRS,
assessed by a trained, but independent rater who was blind
to the treatment condition (active or sham). The BSI was
administered to evaluate suicide risk. These four time-points
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were: at baseline (T1), after the first week of stimulation (T2),
after the second week of stimulation (T3) and 2 weeks after the
last stimulation, i.e., 1 month after baseline (T4). Six months
after baseline, patients were contacted to assess whether or
not they had committed suicide. Patients were randomized
to two groups: during the first week one group received the
active stimulation and the other group started with the sham
condition. They were switched to the other condition during
the second week; see Figure 1 for a flowchart of the study
design.
Intermittent TBS stimulation was applied using a Magstim
Rapid2 Plus1 magnetic stimulator (Magstim Company Limited,
Wales, UK) with a figure-of eight-shaped coil. The resting
motor threshold (rMT) of each individual was determined
on the right abductor pollicis brevis muscle before the
first treatment session (Fitzgerald and Daskalakis, 2012).
A stimulation intensity of 110% of the patient’s rMT was
administered during treatment. We used the Brainsight
neuronavigation system (BrainsightTM, Rogue Research,
Inc.) to identify the site of stimulation (i.e., the center
part of the midprefrontal gyrus [Brodmann 9/46]) based
on a structural cerebral MRI of each individual in order
to accurately target the left dorsolateral prefrontal cortex
(DLPFC). A structural MRI of the brain was performed on a
3T Siemensr Magnetom Trio MRI scanner (Siemens, Erlangen,
Germany). All subjects underwent a T1-weighted MRI scan
of the brain (3D-TFE, TR/TE = 2530/2.58; flip angle = 7◦;
FOV = 220 × 220 mm2; resolution = 0.9 × 0.9 × 0.9 mm3;
number of slices = 176) with a 32 channel SENSE head
coil. iTBS was delivered at five sessions per day during
4 days. One iTBS session consisted of 54 trains of 10
bursts of three stimuli. These stimuli were applied in a
50 Hz frequency: the bursts were repeated every 200 ms.
This resulted in 2 s of stimulation alternated by 8 s
rest periods and 1620 stimuli per session. With a total
of 20 sessions, this yielded a sum of 32,400 stimuli per
complete treatment. For the sham condition, a specially
designed sham coil, looking completely identical as the active
coil and making a similar noise but without delivering
any active stimulation, was placed exactly on the same
target region in the same position. Throughout the whole
treatment (iTBS and sham), patients were blindfolded,
wore earplugs and were kept unaware of the type of
stimulation. Between two sessions, there was a pause
of 15 min.
Statistical Analysis
All data were analyzed using Statistical Package for the Social
Sciences (SPSS; IBM SPSS Statistics for Windows, Version 23.0,
IBM Corp., Armonk, NY, USA). The significance level was set at
p< 0.05 for all analyses.
To examine the effect of the treatment protocol on suicide
risk, mixed linear regression analyses were performed on the
BSI scores with patient as random factors and Order (iTBS-
sham or sham-iTBS) and Time as fixed factors. To further
evaluate whether the main effect on suicidal ideation could not
be attributed to a general improvement of depressive symptoms,
we carried out mixed linear regression analyses on the BSI
scores with factors Time and HDRS responder (on T4). Patients
were considered HDRS-responders when they showed at least a
50% decrease of HDRS score. We applied a similar regression
model replacing the dichotomous variable with the continuous
changes in HDRS scores. To evaluate the differences in BSI
score between the different groups at baseline, we applied
FIGURE 1 | Flowchart of the iTBS-sham-controlled cross-over protocol. Patients were randomized to two groups: group A (n = 22) received iTBS during the
first week and sham in the second week and group B (n = 24) was administered sham stimulation during the first and iTBS in the second week. Stimulation
parameters: 110% resting MT (rMT), 1620 pulses per session in 54 bursts of three with a train duration of 2 s and an intertrain interval of 8 s; five sessions per day
during 4 days per week. Evaluations were carried out at four time-points: at baseline (T1), after the first week of stimulation (T2), after the second week of stimulation
(T3) and 2 weeks after the last stimulation, i.e., 1 month after baseline (T4). iTBS, intermittent Theta Burst Stimulation; MT, Motor Threshold.
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independent-samples-t-tests. Post hoc paired t-tests were done
on the BSI scores at the different time-points for all mentioned
groups.
RESULTS
Three patients were considered drop-out from the study.
One male patient erroneously received two times the active
stimulation. One female patient spontaneously improved after
antidepressant washout and was not stimulated. Another female
patient was considered dropout from the study because of a
suicide attempt (medication overdose) after the first week of
sham iTBS. Data on one additional patient were not included in
the analysis because the baseline BSI score was missing.
Of the 46 patients, 32 subjects reported suicidal ideations at
baseline (T1), which was defined by a BSI score of larger than 1
(Beck et al., 1999). Consequently, all analyses were performed on
these 32 suicidal subjects. The mean BSI score of the group that
had suicidal thoughts (n = 32) was 13.31 (SD = 6.78). Eighteen
patients received sham in the first week while 14 received active
iTBS treatment during the first week. Both groups switched to
the other condition for the second week. There was no significant
difference in baseline BSI scores between the different groups (see
Table 1).
No seizures, hypomanic or manic switches or other serious
adverse events nor suicide attempts were observed during
the treatment phase. Local discomforts at the stimulation site
during treatment or headache during or after the session were
mentioned, but these complaints disappeared spontaneously
after a couple of hours or a single intake of paracetamol.
There were no drop-outs caused by intolerance. None of the
iTBS treated patients committed suicide up to 6 months after
treatment. This was the last time-point of contact with the
participants.
Analyses showed a significant decrease of BSI scores over time
(p < 0.01) between T1 and T2. There was no significant effect of
the order of treatment (sham-iTBS vs. iTBS-sham; p= 0.66) and
no significant interaction effect (p= 0.45; see Figure 2).
At time-point 4 (T4), i.e., 1 month after baseline and 2 weeks
after finalization of the treatment protocol, 18 of the 46 therapy-
resistant depressed patients showed a depression-response, as
defined by a decrease of at least 50% of their HDRS scores. This
means that 39% of these therapy-resistant depressed patients
responded to the stimulation protocol regarding their depressive
symptoms (mean HDRS T1 = 21.50 (SD = 5.57); mean HDRS
T4 = 12.83 (SD = 7.33)). Within the suicidal subgroup, 13
out of 42 patients showed a decrease of at least 50% of the
HDRS scores at time-point T4, which equals 31%. When we
divided this subgroup into HDRS-responders and HDRS-non-
responders to evaluate the effect on suicide risk, the mixed
linear regression model showed a significant decrease in BSI
score in both groups, lasting up to T4 with a significant
effect of Time (p < 0.01) but no significant effect of the
factor ‘‘HDRS-response on T4’’ (p = 0.378) and no significant
interaction effect (p = 0.19; see Figure 3). An independent-
samples-t-test showed no significant difference in BSI score at
baseline between the group of HDRS-responders and HDRS-
non-responders (t(30) = 0.42, p = 0.68). Applying a similar
regression model replacing the dichotomous variable with the
continuous changes in HDRS scores showed similar results:
no significant interaction was found between time and HDRS
change (p= 0.20).
Post hoc paired t-tests on the suicidal subgroup showed a
significant decrease of BSI scores (p < 0.05) between T1 and T2,
T1 and T3 and between T1 and T4, unrelated to active or sham
stimulation and unrelated to depression response at T4 (defined
as a 50% decrease of HDRS score).
In those patients (n = 14) with no suicide risk at baseline
(BSI ≤ 1) we found no significant main effect of Time
and no significant interaction effects indicating that there
was no significant change in BSI scores in this non-suicidal
subgroup.
DISCUSSION
This sham-controlled study shows a decrease of suicide risk
following accelerated iTBS in treatment-resistant unipolar
depressed patients, however, without statistically significant
difference between the effect of active and the sham treatment.
The antisuicidal effect lasted up to 1 month after baseline and
appeared to be independent of the antidepressant effect. None of
the iTBS treated patients committed suicide until 6 months after
treatment. In line with other intensive rTMS treatment studies,
our accelerated iTBS protocol was safe as only decreases in
suicidal ideation were observed (Holtzheimer et al., 2010; Hadley
et al., 2011; Baeken et al., 2013; George et al., 2014). Furthermore,
in patients without suicidal ideation at baseline no significant
increases in BSI scores were found. To our knowledge this is the
TABLE 1 | Beck scale of suicide ideation (BSI) scores.
BSI
T1 T2 T3 T4
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI)
Total group 13.31 (10.52–16.13) 8.22 (5.08–11.61) 7.53 (4.57–10.50) 5.26 (2.47–8.24)
iTBS—sham 13.43 (9.21–17.64) 9.36 (4.46–14.26) 7.57 (3.12–12.02) 5.00 (0.90–9.62)
sham—iTBS 13.22 (9.51–16.94) 7.33 (3.02–11.65) 7.50 (3.57–11.43) 5.44 (1.67–9.22)
Mean BSI scores and 95% CI on time-point T1, T2, T3 and T4 for the suicidal subgroup (n = 32).
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FIGURE 2 | Beck Scale of Suicide ideation (BSI) scores before and
after active and sham treatment. Graphical representation of the BSI mean
scores with Time (baseline (T1), after 1 week of stimulation (T2), after finishing
the treatment protocol (T3) and 2 weeks later (T4)) as within-subjects variable,
and Order (sham > active vs. active > sham) as between-subjects factor.
∗ Indicates significant difference.
first study investigating accelerated iTBS as an intervention to
reduce suicide risk.
The lack of a significant difference between the active and the
sham group after 1 week appears to be in line with the findings
of George et al. (2014) who did not find a significant difference
in effect between the active and sham group after 3 days of
rTMS. Nevertheless, it is clear that the sham group also showed a
significant decrease in suicide ideation after 1 week, indicating
that placebo effects may influence the outcome in such iTBS
studies.
The lack of a significant difference in BSI scores between
the two conditions might be due to the fact that the BSI
score decrease is totally or partly caused by a placebo-effect,
which is mostly caused by hope and beliefs (Mommaerts and
Devroey, 2012). A meta-analysis of all intent-to-treat person-
level longitudinal data of major depressive disorder from 16
randomized controlled trials of fluoxetine hydrochloride and 21
adult trials of venlafaxine hydrochloride, resulted in an estimated
78.9% decrease in the probability of suicidal risk for control
patients after 8 weeks of study participation and a 90.5% decrease
for treated patients (Gibbons et al., 2012). Of note, Iovieno and
Papakostas (2012) described that higher placebo response rates
are correlated with a lower probability to detect a statistically
significant superiority of the drug vs. placebo. Since our study
and the before-mentioned meta-analysis from Gibbons et al.
(2012) also found a high placebo (sham) response rate on BSI
scores, this might explain the absence of significant differences
between the active and sham group after 1 week. Between T3 and
T4 there was no more intervention and no contact between the
FIGURE 3 | BSI score in Hamilton Depression Rating Scale (HDRS)-
responders and non-responders. Graphical representation of the BSI mean
scores with Time (baseline (T1), after 1 week of stimulation (T2), after finishing
the treatment protocol (T3) and 2 weeks later (T4)) as within-subjects variable
and HDRS responders on T4 as between-subjects factor. ∗ Indicates
significant difference.
patients and the caregivers. Interestingly during those 2 weeks
a further significant decrease of BSI scores was obtained. This
suggests that the contact with caregivers is not the major cause
of the improvement.
To further investigate the effects of this accelerated
intermittent Theta Burst protocol, we analyzed the results
1 month after baseline (T4) and found that 39% of these therapy-
resistant depressed patients responded to the stimulation
protocol in terms of their depressive symptoms which is on its
own a very interesting finding. The decrease in suicide risk was
not statistically different between the group of HDRS-responder
vs. the HDRS-non-responder group, indicating that those
patients who showed less than 50% decrease in HDRS-score,
defined as ‘‘HDRS-non-responders’’, did however show a
significant decrease in BSI score. Moreover, the improvement in
suicide ideation lasted up to 1 month after baseline.
The use of a randomized, sham-controlled design in therapy-
resistant and antidepressant-free patients contributes to the
methodological strengths of this study. In addition, the left
DLPFC stimulation site was targeted using a neuronavigation
system which is more precise than the standard 5 cm technique
that has been applied in all mentioned previous studies
(Fitzgerald et al., 2009; Holtzheimer et al., 2010 ; Hadley et al.,
2011; Keshtkar et al., 2011; Wall et al., 2011; George et al.,
2014). Moreover, our sample size is relatively large, especially
taking into account the difficulties in recruiting therapy-resistant
depressed and suicidal patients that are antidepressant-free, such
as ethical and safety issues, and also compared to other studies
(Hadley et al., 2011; Wall et al., 2011). On the other hand it is
rather small from a statistical point of view.
Frontiers in Human Neuroscience | www.frontiersin.org 5 September 2016 | Volume 10 | Article 480
Desmyter et al. iTBS for Suicidal Depressed Patients
Another strength is the fact that we selected a diagnostically
homogeneous group of unipolar depressed patients with suicidal
ideations where other studies of interventions for suicide
ideations often combine unipolar and bipolar depressed subjects
or include non-depressed personality disordered suicidal patients
or patients with other comorbidities (Hadley et al., 2011; Wall
et al., 2011; George et al., 2014). We used an extensive suicide
assessment scale to assess the suicide risk instead of only one
suicide item of a depression rating scale, as has been done
by other research groups (O’Reardon et al., 2007; Holtzheimer
et al., 2010; Keshtkar et al., 2011). The evaluation at 1 month
after baseline and 6 months after baseline is longer than what
was reported in most previous studies. Furthermore, iTBS was
administered in monotherapy, i.e., without concomitant anti-
depressant medication whereas other studies applied rTMS as
an adjunctive treatment (Holtzheimer et al., 2010; Hadley et al.,
2011; Keshtkar et al., 2011; Wall et al., 2011; George et al.,
2014). This made it possible to evaluate the accelerated iTBS
protocol without the confounding factor of another treatment.
Taking into account the potentially large placebo-effects in
this population, the treatment protocol has the advantage over
previous reports in being sham-controlled (Brunoni et al., 2009;
Gibbons et al., 2012).
A possible pitfall is the cross-over design which necessitates
the evaluation of the difference between active and sham
stimulation on T2 in order to avoid carry-over effects that could
be expected during the second week. As mentioned, the maximal
effect of the treatment is not expected so quickly (i.e., T2 is
only 3 days after the last stimulation session) so this evaluation
possibly comes too soon to find a significant difference between
these two groups. This assumption is based on the proposed
neurophysiological effects of TBS: it is thought to create more
robust neuroplasticity effects, which possibly become apparent
later in time after treatment. (Chung et al., 2015) Interestingly,
between T3 and T4 there was no more stimulation and no
contact between the patients and the caregivers. And during
those 2 weeks a further significant decrease of BSI scores was
obtained. On the other hand, it would have been unethical to
choose not to treat one group of these severely ill patients to
obviate the cross-over protocol or to wait any longer between
the two conditions. Although the BSI is a valid and commonly
used instrument, scoring assumes that the total score equals
to zero if the patient responds ‘‘no’’ to the first five screening
questions. Consequently it quickly turns to a score of ‘‘zero’’ and
the range of low scores is limited, therefore possibly limiting the
interpretation possibilities.
A disadvantage of the therapy-resistance and lack of
concomitant antidepressant, antipsychotic or mood-stabilizing
treatment is the fact that our patient sample is less generalizable
to a clinical population of suicidal patients that arrive at the
emergency ward.
The findings from this study show that this accelerated iTBS
protocol is safe to be applied to depressed, suicidal patients and
that there is an important effect of sham stimulation. The iTBS
protocol also resulted in a significant decrease of suicide risk
in depression-non-responders. Further research is necessary to
confirm these findings. Such research should be performed in
sham-controlled designs in order to study the effects of rTMS
in monotherapy and, when confirmed, in more naturalistic
conditions.
CONCLUSION
Suicide is a major health concern and effective interventions
to rapidly reduce suicide risk are lacking. The currently used
accelerated iTBS protocol appears to be a feasible and safe
treatment for depressed patients with suicidal ideation. The
protocol was associated with a significant decrease in suicide
risk, lasting up to 1 month, unrelated to active or sham
stimulation and unrelated to depression-response. One should
thus note an important effect of sham stimulation. Interestingly,
the observed decrease in suicide risk was not only due to
an improvement of depression and 2 weeks after treatment
a persistent decrease of suicidal thoughts was found even in
depression non-responders. The current study has the advantage
above previous studies in using a sham-controlled design to
study the effects of neuronavigated accelerated iTBS in an
antidepressant-free diagnostically homogenous group. rTMS
should be further investigated as an acute intervention for suicide
risk in unipolar depression in sham-controlled trials.
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